EHR interoperability survey: Providers struggling, not optimistic

With all the talk of interoperability (and the lack thereof), it's no big surprise that the latest report on health IT finds that most EHR vendors' products are not interoperable.

In health IT research firm KLAS' report, less than half of providers said that they EHR vendor is interoperable with other vendors. Only 20 percent of providers are "optimistic" about vendor collaboration initiatives such as the CommonWell Health Alliance, an independent trade association of health IT vendors.

On the other hand, 82 percent of providers said they have been at least "moderately successful" with interoperability, but that's primarily due to their own efforts. Just 6 percent of those providers reported having achieved an advanced state.

"There has been a lot of public discussion about the lack of interoperability among (EHR) vendors," said report author Colin Buckley in a statement. "The truth is that most providers feel at least moderately successful with interoperability today, but most say that success is due to their own efforts. They wonder how well prepared their vendor will be for the future."  

Access the complete report.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.